WillItSurvive
Medical technology and health companies · United States

Medtronic

medtronic.com ↗

Medtronic makes implanted and hospital medical devices across cardiac, spine, neuro, and surgical robotics.

Hard to displace
Assessed 22 July 2026 · Evidence as of 22 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 22 July 2026 · Checkable from H1 2027 · Every call on the record Checkpoint: FDA 510(k) decision on Hugo for general and gynecologic surgery (filed June 2026)
The call

Medtronic's growth is real and its regulatory position is hard to breach, but robotic surgery remains Intuitive Surgical's game to lose.

Medtronic designs and sells medical devices like pacemakers, surgical robots, and monitoring equipment to hospitals and patients. It is very difficult to copy or replace because the FDA requires years of testing before any new device can be sold, Medtronic owns tens of thousands of patents, hospitals have used its equipment for decades, and patients with implanted devices cannot easily switch. The one thing to watch is whether Intuitive Surgical's newer robot called Hugo can win FDA approval and steal business from Medtronic's robot products; if Hugo succeeds, Medtronic's robot division becomes more of a growth opportunity, but if Intuitive stays dominant, Medtronic's robot business stays in second place.

Why
01
AI pressure: None apparent. AI cannot get FDA clearance to control implanted devices or carry liability, so Medtronic builds AI like Touch Surgery Aide onto its own hardware instead of losing to it. Could AI do the core job? Unlikely.
02
Bigger players: Intuitive Surgical. Intuitive holds over 70% of robotic surgery with da Vinci; Medtronic's Hugo remains a distant number two awaiting broader FDA clearances. Could a giant copy it? No, they are blocked.
03
What protects it. FDA clearance hurdles, 45,000+ patents, and hospitals already wired for Medtronic's implanted hardware make switching costly and slow.
What would change this call
FDA ruling on Hugo's 510(k) filings for general and gynecologic surgery (filed June 2026). Clearance would let Medtronic challenge Intuitive Surgical's robotic surgery dominance.
Outcome and scope of spinal-cord-stimulator mass-tort litigation with July 2026 filings. Would show whether liability exposure meaningfully impairs the neuro franchise.
MiniMed's standalone financial results as a public company through 2026-2027. Would show whether the diabetes unit was a drag Medtronic is better off without.
Key numbers
  • FY26 revenue $36.364B, up 8.4% (2026-06-03)
  • FY26 free cash flow $5.4B, strongest since 2022 (2026-06-04)
  • MiniMed IPO raised $560M, valued at ~$5.6B (2026-03-06)
Named risks
  • Active spinal cord stimulator mass-tort litigation with new suits filed July 22, 2026. Severity: medium
  • Distant #2 to Intuitive Surgical in robotic surgery with pending 510(k) outcomes uncertain. Severity: medium
  • Multiple 2026 FDA Class II device recalls (BioMedicus, DLP cannulas) could expand scope. Severity: medium
  • Tariff and margin headwinds flagged in FY27 guidance amid mixed analyst price-target cuts. Severity: medium
  • MiniMed diabetes spinoff execution risk after IPO priced below marketed range in March 2026. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Intuitive Surgicallosing toIntuitive holds est. 70%+ robotic surgery share vs Hugo distant #2, as of March 2026
Boston Scientificgaining onMedtronic reported gaining PFA ablation share vs BSX's ~58-60% lead amid BSX guidance cut, April 2026
Abbott LaboratoriescontestingAbbott leads medtech revenue at $44.3B vs Medtronic's $34.8-36.4B in 2025, per July 2026 ranking
Johnson & Johnson MedTechcontestingJ&J MedTech revenue ~$34B, closely trailing Medtronic in 2025 industry rankings
Questions people ask
Is Medtronic profitable in 2026?
Yes. Medtronic reported FY2026 (ended April 24, 2026) net income attributable to the company of $4.801B on revenue of $36.364B, with adjusted EPS of $5.53 for the year and free cash flow of $5.4B, the strongest since 2022, per its June 3, 2026 earnings release.
Could AI replace Medtronic's medical devices?
No. AI cannot obtain FDA clearance for autonomous device control or carry product liability, so Medtronic's regulated hardware (pacemakers, spinal implants, Hugo robot) stays legally required. AI tools like Touch Surgery Aide, unveiled July 21, 2026, are layered onto Medtronic's cleared devices rather than replacing them.
Who is Medtronic's biggest competitor?
In robotic surgery, Intuitive Surgical holds an estimated 70%+ share with Medtronic's Hugo system a distant number two as of March 2026. In cardiac ablation, Boston Scientific has historically led with roughly 58-60% share in 2024-25, though Medtronic was reported gaining ground in early 2026.
Did Medtronic spin off its diabetes business?
Yes. Medtronic announced the Diabetes business separation on May 21, 2025, named it MiniMed in June 2025, and completed its Nasdaq IPO (ticker MMED) on March 6, 2026, raising $560M below its marketed range at roughly a $5.6B valuation, with about 8,000 employees moving to the new company.
Is Medtronic a safe company to join right now?
Officially reported headcount held flat around 95,000 from FY2022 through FY2026 per company filings as of July 5, 2026, though 81 diabetes-related Northridge, CA positions were cut in February 2026 ahead of the MiniMed spinoff, and active job postings reportedly fell sharply in 2025.
Is Medtronic facing lawsuits over its devices?
Yes. New spinal cord stimulator lawsuits against Medtronic, Abbott, Boston Scientific, and Nevro were filed July 22, 2026 challenging FDA oversight of device modifications. Medtronic won partial dismissal in a Minnesota federal SCS case on July 14-16, 2026, though one plaintiff's manufacturing-defect claim survived.
Timeline
  • 2026-07-22New spinal cord stimulator lawsuits filed against Medtronic, Abbott, Boston Scientific, Nevro over FDA oversight
  • 2026-07-21Unveiled Touch Surgery Aide AI surgical compute platform with FDA-cleared Instrument Exit Point for Hugo robot
  • 2026-07-16Won partial dismissal in Minnesota federal spinal cord stimulator lawsuit
  • 2026-06-03Reported FY2026 revenue of $36.364B, highest annual growth in 10 years; launched GAiTEWAY platform
  • 2026-06-03Declared 49th consecutive annual dividend increase to $0.72/share quarterly
  • 2026-03-06MiniMed diabetes spinoff completed Nasdaq IPO (MMED), raising $560M at ~$5.6B valuation
  • 2026-02-25Cut 81 diabetes-related positions at Northridge, CA site ahead of spinoff
  • 2025-12-22MiniMed filed for IPO showing FY2025 sales of $2.72B and $198M loss
  • 2025-06-12Announced 'MiniMed' as name for planned diabetes spinoff company
  • 2025-05-21Announced intent to separate Diabetes business into standalone company
Revision history
22 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Epic SystemsPro MedicusCochlear Limited
More in Medical technology and health companies →
Sources